These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9830809)

  • 1. Severe immune thrombocytopenia during formestane treatment.
    Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
    Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of formestane in postmenopausal women with breast cancer.
    Joseph JK; Lim AK
    Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formestane for advanced breast cancer in postmenopausal women.
    Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer].
    Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
    Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced breast cancer with formestane.
    Murray R; Pitt P
    Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K; Jonat W; Höffken K
    Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
    Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
    J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
    Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
    Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
    Nisslein T; Freudenstein J
    Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
    Wiseman LR; McTavish D
    Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
    Dowsett M
    Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
    Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
    Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
    MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
    Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.